Research SummaryKey Findings

What research findings exist on Kisspeptin regarding reproductive hormones and reproductive function?

Intermittent subcutaneous kisspeptin-10 can sustain gonadotropin and testosterone stimulation for 12 days. Another study reported: LH initially rises and then partially declines, providing physiological data for continuous dosing response.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

Comparison of study design and results

Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.

LiteratureStudy subjects and designObservation and discoveryScope of Explanation
2026 · PMID 42549827Randomized single-blind placebo study in healthy malesIntermittent subcutaneous kisspeptin-10 can sustain gonadotropin and testosterone stimulation for 12 days.Endocrine physiological endpoints, do not demonstrate fertility or long-term clinical benefits.
2026 · PMID 422304853 healthy men; 24-hour continuous infusionLH first rises and then partially falls back, providing physiological data for continuous drug administration response.Extremely small sample; not an efficacy study for reproductive disease treatment.
2025 · PMID 40036336Human randomized, double-blind, placebo crossover; kisspeptin-54Stimulated LH but did not change anxiety indicators, providing physiological and tolerability clues for reproductive therapy development.54 differs from the 10-amino acid form; shouldn’t be promoted as anti-anxiety.

References

Human Study2026REF. 01

How is the sustained hormone stimulation of Kisspeptin-10?

Research Findings

Intermittent subcutaneous kisspeptin-10 can sustain gonadotropin and testosterone stimulation for 12 days.[1] ↗

Study Design

Randomized single-blind placebo study in healthy males

Scope & Limitations

Endocrine physiological endpoints, do not demonstrate fertility or long-term clinical benefits.

View the Article Title and Full Citation＋

Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men.

Yeung AC, Phylactou M, Koysombat K, Tsoutsouki J, Nyunt SW, Young M, Patel AH, Daniels E, Pierret ACS, Mills EG, Comninos AN, Abbara A, Dhillo WS.

European Journal of Endocrinology · Volume and Issue Year 2026
First published 2026-08-01 · PMID 42549827
DOI 10.1093/ejendo/lvag134

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2026REF. 02

How does LH response change after continuous infusion?

Research Findings

LH first rises and then partially falls back, providing physiological data for continuous drug administration response.[2] ↗

Study Design

3 healthy men; 24-hour continuous infusion

Scope & Limitations

Extremely small sample; not an efficacy study for reproductive disease treatment.

View the Article Title and Full Citation＋

Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.

Naveed A, Lippincott MF, Stamou M, Balasubramanian R, Bryant NK, Seminara SB.

Hormones (Athens, Greece) · Volume/Issue Year 2026
First published 2026-06-02 · PMID 42230485
DOI 10.1007/s42000-026-00795-y

Published · Original ResearchPubMed ↗Journal Article ↗
Human Study2025REF. 03

Does a change in reproductive hormones also mean improvement in anxiety?

Research Findings

Stimulated LH but did not change anxiety indicators, providing physiological and tolerability clues for reproductive therapy development.[3] ↗

Study Design

Human randomized, double-blind, placebo crossover; kisspeptin-54

Scope & Limitations

54 differs from the 10-amino acid form; shouldn’t be promoted as anti-anxiety.

View the Article Title and Full Citation＋

Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans.

Mills EG, Thurston L, Yang L, Hunjan T, Phylactou M, Patel B, Clarke SA, Izzi-Engbeaya C, Tsoutsouki J, Young M, Bech P, Ertl N, Wall MB, Abbara A, Comninos AN, Dhillo WS.

The Journal of Clinical Endocrinology and Metabolism · Volume, Issue, Year 2025
First published 2025-10-01 · PMID 40036336
DOI 10.1210/clinem/dgaf128

Published · Original ResearchPubMed ↗Journal Article ↗

Common issues and corresponding evidence

What research findings exist on Kisspeptin regarding reproductive hormones and reproductive function?＋

Intermittent subcutaneous kisspeptin-10 can sustain gonadotropin and testosterone stimulation for 12 days. Another study reported: LH initially rises and then partially declines, providing physiological data for continuous dosing response.[1] ↗ [2] ↗

Does increasing reproductive hormones with Kisspeptin represent improved fertility?＋

Does not represent. The selected study mainly measured LH, gonadotropins, and their dynamic changes, and also needs to distinguish between kisspeptin-10 and -54; physiological endpoints cannot replace pregnancy or fertility outcomes.[1] ↗ [2] ↗ [3] ↗

Kisspeptin—these conclusions apply to which study populations?＋

Randomized single-blind placebo study in healthy males; 3 healthy males; 24-hour continuous infusion; human randomized double-blind placebo crossover; kisspeptin-54. Endocrine physiology endpoints, does not demonstrate fertility or long-term clinical benefit.[1] ↗ [2] ↗ [3] ↗

Kisspeptin

Return to catalog specifications and batch file verification entry.

↗